Maarten van der Doelen

Chapter 7

Group DDR + N = 28 P

ECOG performance status, n (%) 87 ECOG 0 62 (71.3) 43 (70.5) 19 (73.1) 1.000 ECOG 1 22 (25.3) 16 (26.2) 6 (23.1) ECOG 2 3 (3.4) 2 (3.3) 1 (3.8) Pain score, median (IQR) 79 2 (0-3) 2 (0-4) 1 (0-2) 0.284 Opioid use, n (%) 84 24 (28.6) 14 (23.3) 10 (41.7) 0.093 PSA level, median (IQR), µg/l 93 59.0 (19.1-168.9) 69.0 (23.5-174.0) 37.0 (14.9-126.3) 0.297 LDH level, median (IQR), U/l 46 217.0 (193.3-246.0) 224.5 (197.3-254.8) 211.0 (173.5-227.8) 0.196 a Docetaxel was administered as upfront chemotherapy in hormone sensitive prostate cancer in 15 patients (16.3%). b According to ALSYMPCA trial criteria. c Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity. ALP, alkaline phosphatase; DDR, DNA damage repair; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; ISUP, International Society of Urological Pathology; PSA, prostate-specific antigen. ALP level, median (IQR), U/l 93 124.0 (85.0-186.5) 132.0 (90.0-191.0) 102.5 (75.0-170.3) 0.282 ALP < 115, n (%) 44 (47.3) 29 (44.6) 15 (53.6) 0.427 ALP ≥ 115, n (%) 49 (52.7) 36 (55.4) 13 (46.4)

Group DDR - N = 65

N = 93

Complete cohort

N

Table 1. Continued.

182